These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30975451)

  • 1. Solid Science for the Upside but Lack of Solid Science for the Downside-Towards Cutting-edge Prostate-cancer Screening.
    Steineck G; Akre O; Bill-Axelson A
    Eur Urol; 2019 Jul; 76(1):52-53. PubMed ID: 30975451
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
    Braillon A; Dubois G
    J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
    [No Abstract]   [Full Text] [Related]  

  • 3. An Overview of Current Screening and Management Approaches for Prostate Cancer.
    Akram ON; Mushtaq G; Kamal MA
    Curr Drug Metab; 2015; 16(8):713-8. PubMed ID: 26560323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.
    Rodriguez JF; Eggener SE
    Radiol Clin North Am; 2018 Mar; 56(2):187-196. PubMed ID: 29420975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 6. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.
    Stampfer MJ; Jahn JL; Gann PH
    J Natl Cancer Inst; 2014 Mar; 106(3):dju026. PubMed ID: 24610908
    [No Abstract]   [Full Text] [Related]  

  • 7. Early detection of prostate cancer continues to support rational, limited screening.
    Partin AW
    J Urol; 2013 Aug; 190(2):427-8. PubMed ID: 23688640
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should you skip your PSA test? The science is uncertain for now, so arm yourself with deep knowledge of the pros and cons of prostate cancer screening.
    Harv Mens Health Watch; 2012 Oct; 17(3):1, 7. PubMed ID: 23175860
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate cancer screening "reloaded".
    Gomella LG
    Can J Urol; 2010 Apr; 17(2):5057. PubMed ID: 20398441
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prostate cancer screening].
    Rodríguez-Carlin A; Castillo O
    Medwave; 2016 Jul; 16(6):e6504. PubMed ID: 27532121
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.
    Tikkinen KAO; Dahm P; Lytvyn L; Heen AF; Vernooij RWM; Siemieniuk RAC; Wheeler R; Vaughan B; Fobuzi AC; Blanker MH; Junod N; Sommer J; Stirnemann J; Yoshimura M; Auer R; MacDonald H; Guyatt G; Vandvik PO; Agoritsas T
    BMJ; 2018 Sep; 362():k3581. PubMed ID: 30185545
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate Cancer Screening.
    Pinsky PF; Prorok PC; Kramer BJ
    N Engl J Med; 2017 Jun; 376(24):2402. PubMed ID: 28614680
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate Cancer Screening.
    Walsh PC
    N Engl J Med; 2017 Jun; 376(24):2401-2. PubMed ID: 28614679
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Horwich A; Parker C; de Reijke T; Kataja V;
    Ann Oncol; 2013 Oct; 24 Suppl 6():vi106-14. PubMed ID: 23813930
    [No Abstract]   [Full Text] [Related]  

  • 16. Alternative prostate cancer screening strategies.
    Labrecque M; Aprikian A
    Ann Intern Med; 2013 May; 158(10):778. PubMed ID: 23689773
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Taneja SS
    J Urol; 2016 Dec; 196(6):1677. PubMed ID: 27845108
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Taneja SS
    J Urol; 2016 Feb; 195(2):350-1. PubMed ID: 26852972
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of prostate cancer: can we have our cake and eat it too?
    Masterson TA; Cary C; Cheng L
    Expert Rev Anticancer Ther; 2016; 16(3):247-9. PubMed ID: 26760708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.